The Use of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle to Treat Sleep Bruxism
Nocturnal Bruxism
About this trial
This is an interventional treatment trial for Nocturnal Bruxism focused on measuring Nocturnal bruxism, Botulinum toxin, Masseter muscle, Electromyography
Eligibility Criteria
Inclusion Criteria: Moderate to severe pain in the masseter muscles during clinical examination. Age range between 18 and 40 years. Tooth-grinding sounds corroborated by family members or caregivers. Attrition in occlusal surface of posterior teeth. Exclusion Criteria: Loss two posterior teeth or more (except for third molars). Fixed or movable prosthodontics for more than four dental units. Advanced malocclusion (Class II occlusion Model II - deep bite - open bite). Temporomandibular disorders. Pain in the orofacial region. Insomnia. Known botulinum toxin allergy. Pregnancy. Neuromuscular disease. Bleeding disorders. Antibiotic therapy, pulmonary disease that produced coughing during sleep. Infectious skin lesion at the site of the injection.
Sites / Locations
- University of Damascus
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Injection group
Placebo group
In this group, patients will be injected with 10 MU of botulinum toxin type A in the masseter muscle.
In this group, patients will prick twice in the masseter muscle.